Receptor tyrosine kinase inhibition by regorafenib/sorafenib inhibits growth and invasion of meningioma cells

CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2006-2010

Quinn T. Ostrom, Haley Gittleman, P Farah et al. · Neuro-Oncology · 2013 · 12.1K citations · Full text

Medicine, Neurology, Oncology +14

BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis

Scott M. Wilhelm, Christopher Carter, LiYa Tang et al. · Cancer Research · 2004 · 4K citations · Full text

Medicine, Oncology, Pharmacology +17

CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012

Quinn T. Ostrom, Haley Gittleman, Jordonna Fulop et al. · Neuro-Oncology · 2015 · 2.2K citations · Full text

Medicine, Oncology, Cancer Epidemiology +12

Regorafenib (BAY 73‐4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity

Scott M. Wilhelm, Jacques Dumas, Lila Adnane et al. · International Journal of Cancer · 2010 · 1.3K citations · Full text

Medicine, Oncology, Pharmacology +17

Genomic Analysis of Non- <i>NF2</i> Meningiomas Reveals Mutations in <i>TRAF7</i> , <i>KLF4</i> , <i>AKT1</i> , and <i>SMO</i>

Victoria Clark, E. Zeynep Erson‐Omay, Akdes Serin et al. · Science · 2013 · 887 citations · Full text

Medicine, Genetics, Oncology +16